Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International publ : invites to virtual Capital Markets Day 11 May

04/29/2020 | 05:39am EST

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14.00 to 16:00.

Biovica is nearing market launch of DiviTum[®] in the US for the monitoring of metastatic breast cancer treatments. DiviTum[®] is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After an FDA approval, the large market for patient monitoring will become available.

We therefore invite you to a virtual Capital Markets Day on 11 May 2020 at 2:00 to 4:00 pm.

Link will be found at Biovicas website: www.biovica.com/biovica/investor-relations/events/ questions can be sent to ir@biovica.com

At the Capital Markets Day Robert Dann, SVP Marketing and US Business and Henrik Winther SVP Business Development, will present the plan for the market launch of DiviTum[®], oncologist Samuel Rotstein from Karolinska Hospital will present his views on the value DiviTum[®] could bring patients and the healthcare system, and CEO Anders Rylander will give an update on Biovica's current situation.

Welcome!

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum[®] measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum[®] is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

https://news.cision.com/biovica-international-ab/r/biovica-invites-to-virtual-capital-markets-day-11-may,c3100256

https://mb.cision.com/Main/14910/3100256/1238864.pdf

https://news.cision.com/biovica-international-ab/i/2p5a0299-pink,c2779242

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about BIOVICA INTERNATIONAL AB (PUBL)
2020BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..
AQ
2020BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..
AQ
2020BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..
AQ
2020BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
AQ
2020BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
AQ
2020BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
AQ
2020Biovica Year-end Report for 2019/2020
AQ
2020BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
AQ
2020BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..
AQ
2020BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,64 M -4,64 M
Net cash 2021 134 M 16,1 M 16,1 M
P/E ratio 2021 -31,5x
Yield 2021 -
Capitalization 1 244 M 150 M 150 M
EV / Sales 2021 370x
EV / Sales 2022 26,0x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 44,00 SEK
Spread / Highest target 134%
Spread / Average Target 52,3%
Spread / Lowest Target -29,5%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors